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Abstract
The inflammasome is a protein complex that is comprised of an intracellular sensor that is
typically an NLR protein, the pro-protein, procaspase-1 and adaptor molecule ASC.
Inflammasome activation leads to caspase-1 maturation and the processing of its substrate, IL-1β
and IL-18. Although initially the inflammasome was described as a complex that affects infection
and inflammation, recent evidence suggests that inflammasome activation influences a host of
metabolic disorders including atherosclerosis, type 2 diabetes, gout and obesity. Another aspect
regarding inflammation in general and inflammasome in specific is that the activation process has
a profound effect on aerobic glycolysis, or the Warburg effect. How the Warburg effect might be
link to inflammation and inflammasome activation is a novel concept to contemplate.
The incidence of metabolic disorders such as obesity, type 2 diabetes (T2D) and
atherosclerosis has increased dramatically during recent decades, and these diseases
constitute some of the most serious threats to public health. Chronic inflammation is a key
common feature of metabolic disorders. Many inflammatory mediators such as tumor
necrosis factor (TNF), interleukins and cytokine-like proteins known as adipokines have
been linked to the development of multiple forms of metabolic disorders 1, 2. Interleukin
(IL)-1β is a prominent pro-inflammatory cytokine since it can efficiently cause the
generation of other inflammatory mediators through IL-1 receptor signaling, thus initiating a
self-amplifying cytokine network 3. As a result, IL-1β is postulated to play an important role
in the pathogenesis of metabolic disorders. Indeed, studies employing the recombinant IL-1
receptor antagonist (IL-1RA) anakinra have been tested in T2D, with some encouraging
results 4. Recent clinic trials also suggest that non-inflammasome cytokines TNF contributes
to impaired glucose homeostasis and insulin resistance in patients with T2D 5–7. Therefore,
it is highly possible that both IL-1β and TNF may drive chronic inflammation in a
cooperative manner, which highlights the importance of combined immunotherapy against
multiple inflammatory cytokines. This review will focus on the possible role of the
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inflamamsome complex which is important for the maturation of IL-1β in a variety of
metabolic disorders. We will also examine how metabolic alterations in cells including the
so-called “Warburg effect” of aerobic glycolysis contribute to inflammatory processes
relevant for these diseases. While most of the data are based on animal models, the potential
translational relevance will be underscored.
The inflammasome in diabetes and obesity
Inflammasome is a large multimeric danger-sensing platform, which promotes auto-catalytic
activation of the cysteine protease, caspase-1, and mediates the cleavage of inactive pro-
IL-1β and IL-18 among other proteins into their active forms 8, 9. Several recent studies have
provided strong evidence to suggest a critical role of the NLRP3 inflammasome in the
development of insulin resistance using gene-deletion mice 10–14. Genetic ablation of
NLRP3 (Nlrp3−/−) or the NLRP3 inflammasome-associated molecules such as ASC (also
known as PYCARD; Pycard−/−) and caspase-1 (Casp1−/−) resulted in improved glucose
tolerance and insulin sensitivity after high-fat diet (HFD) feeding, therefore linking the
NLRP3 inflammasome to insulin resistance in a number of studies. Several studies have
explored how a HFD in mice might contribute to T2D and the role played by inflammasome
proteins. Ceramide, the specific product of long-chain saturated fatty acid metabolism, can
cause caspase-1 activation and IL-1β release in macrophages from wild-type (WT) mice but
not in macrophages from Nlrp3−/− mice 12. The saturated free fatty acid (FFA) palmitate,
but not unsaturated FFA, induces the activation of caspase-1 and the cleavage of IL-1β and
IL-18 in an NLRP3- and ASC-dependent manner 13. Furthermore, palmitate signals through
an AMP-activated protein kinase (AMPK)-autophagy-mitochondrial reactive oxygen species
(mROS) pathway to activate the NLRP3 inflammasome. An NLRP3 inflammasome-
dependent process affects insulin target tissues such as liver, muscle and adipose tissues (Fig
1). Therefore, these studies explore the mechanisms of NLRP3 inflammasome activation by
danger signal molecules associated with saturated FFA metabolism, and highlight the
importance of NLRP3 inflammasome activation in the development of insulin resistance.
Interestingly, a widely used insulin secretagogue (Glyburide) provides a linkage between
insulin homeostasis and the NLRP3 inflammasome activation. For example, Glyburide can
inhibit NLRP3 inflammasome-mediated caspase-1 activation and both IL-1β and IL-18
release 15.
In addition to the essential role of the NLRP3 inflammasome and IL-1β in the impairment of
insulin signaling in insulin target liver, muscle and adipose tissues, IL-1β also promotes β-
cell dysfunction and cell death directly 16. Islet amyloid polypeptide (IAPP; also known as
amylin) has been identified as a key inducer of NLRP3 inflammasome activation and IL-1β
cleavage 17. IAPP, a hormone that is secreted together with insulin, is deposited in the islet
interstitium of patients with T2D and is considered to be a significant danger risk for
T2D 18. IAPP forms amyloid structures, and amyloid particles have previously been shown
to activate the NLRP3 inflammasome 8. Therefore, it has been proposed that IAPP
oligomers activate the NLRP3 inflammasome and IL-1β cleavage in a manner similar to
other crystalline activators of the NLRP3 inflammasome 17. Other studies suggest that a
high level of glucose induces β-cell production and release of IL-1β in vitro, which then
promotes functional impairment and apoptosis of β-cell in an autocrine manner 10, 19.
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However, this effect seems to be islets specific, since high level of glucose fails to promote
IL-1β release induced by IAPP in bone marrow-derived dendritic cells. Instead, sufficient
glucose is required for NF-κB-dependent, but NLRP3 inflammasome-independent, pro-
IL-1β and IL-6 production 17. The molecular mechanism underlying glucose-induced IL-1β
release by islets remains to be determined, and will be discussed later.
Another potential regulatory mechanism of inflammasome activation during obesity and
insulin resistance is autophagy. Autophagy is a cell intrinsic mechanism for the degradation
and recycling of cellular components 20. Genetic variants of the autophagy gene ATG16L1
have been linked to Crohn’s disease 21–24. Deletion of either the Atg16l1 or Atg7 autophagic
gene in mouse macrophages leads to increased caspase-1 activation and IL-1β release, but
not TNF and IL-6 generation. This was observed in response to treatment with either
lipopolysaccharide (LPS) alone or LPS in conjunction with NLRP3 inflammasome
activators such as ATP and monosodium urate (MSU) 25. These findings have been recently
confirmed and more detailed molecular mechanisms involving disrupted mitochondrial
homeostasis have been explored 13, 26, 27. Deletion of autophagy gene 18, 19 or palmitate
treatment 13 inhibits autophagy, which subsequently leads to the accumulation of
dysfunctional mitochondria and increased mitochondrial ROS (mROS) generation. These
events activate the NLRP3 inflammasome. Nakahira et al. suggests that the leakage of
mitochondrial DNA into cytosol upon autophagy inhibition may serve as a coactivator for
inflammasome activation 26. These studies provide evidence that autophagy negatively
regulates NLRP3 inflammasome activation by maintaining mitochondrial homeostasis.
Accordingly, defective autophagy has been observed in the liver of both genetic (ob/ob) and
diet-induced (HFD feeding) obesity animal models 28. Although the mechanism by which an
obese condition leads to defective autophagy has not been characterized, AMPK and/or
mTOR signaling pathways may be potential candidate of upstream modulators, since these
two evolutionally conserved signaling pathways have been shown to regulate autophagy by
direct phosphorylation of ATG1 29, 30. Therefore, a strong possibility is that defective
autophagy associated with obesity and insulin resistance may promote inflammasome
activation and amplify inflammatory network in insulin target tissues.
In addition to a direct effect of the NLRP3 inflammasome on innate immunity, recent
studies show that IL-1β and IL-18 play an essential role in shaping adaptive immune
responses in several animal models such as experimental autoimmune encephalomyelitis
(EAE), arthritis and cytotoxic T cell (CTL)-mediated anti-tumor responses 31. Specifically,
IL-1 promotes the differentiation of T helper 17 (TH17) lineage by increasing the expression
of IRF4 and RORγt, two essential transcription factors involved in TH17 differentiation 32,
whereas IL-18, in synergy with IL-12, induces IFN-γ-producing TH1 cells 33. More
importantly, the differentiation of human TH17 cells requires the presence of IL-1β 34, 35.
Based on recent studies suggesting that the aberrant accumulation and activation of
lymphocytes in adipose tissues (including both T and B cells) impair insulin sensitivity in
obesity-induced insulin resistance 36–40, it is reasonable to argue that NLRP3 inflammasome
activation might lead to lymphocyte accumulation and activation in obesity and insulin
resistance. Indeed, significantly decreased numbers of both CD4+ and CD8+ effector
memory T cells have been observed in the adipose tissue of Nlrp3−/− mice after HFD
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feeding 12, suggesting that the NLRP3 inflammasome-regulated adaptive immune response
may also contribute to insulin resistance.
It has been long-postulated that obesity is a strong risk factor for insulin resistance and T2D,
and this is partially mediated through enhancing chronic inflammation in insulin target
tissues 1. Recently it has been proposed that the inflammasome affects adipocyte
differentiation and HFD-induced obesity 11, 14. Stienstra et al. demonstrated that NLRP3-
dependent caspase-1 and IL-1β activation inhibits adipocyte differentiation and insulin
signaling 11. This same group also found that the genetic ablation of NLRP3 inflammasome
or pharmacological inhibition of caspase-1 provides a beneficial effect in HFD-induced
obesity, presumably through increasing energy expenditure 14. However, the protective role
played by NLRP3 inflammasome in HFD-induced obesity was not uniformly observed
because two other studies have not confirmed these findings 12, 13. These studies did not
observe a difference in total body weight between Nlrp3−/− mice and WT mice after HFD
feeding 12, 13, although NLRP3 seems to play a role in adipocyte morphology 12. The reason
for the different observations is currently unknown, but may potentially involve subtle
differences such as HFD from different sources. Another important potential link to obesity
is the observation that there is enhanced β-oxidation of fatty acids in Casp1−/− mice. This is
likely to be due to decreased IL-1β since IL-1β limits β-oxidation and will therefore decrease
adiposity. Accordingly, a caspase-1 inhibitor led to higher fat oxidation rates in obese
mice 11. NLRP3 inflammasome activation might therefore promote obesity.
The inflammasome in atherosclerosis
Atherosclerosis has components of a chronic inflammatory disease characterized by the
accumulation of lipid components and recruitment of immune cells in atherosclerotic
lesions 41, 42. When low-density lipoprotein (LDL), a cholesterol-containing lipoprotein, is
retained in the artery wall, it leads to vascular inflammation and cholesterol accumulation,
partially as cholesterol crystals 41, 42. Among the inflammatory mediators, IL-1β has been
shown to play a significant role in promoting the development of lipid plaques and also
destabilizing the plaques in mice. In Apoe−/− mice which spontaneously develop
atherosclerosis due to hypercholesterolemia, IL-1β deficiency results in an attenuated
development of atherosclerotic lesions 43. The application of IL-1RA has been shown to
prevent lesion development 44. Therefore, experimental animal studies support the concept
that IL-1β collaborates together with other proinflammatory cytokines such as TNF to
exacerbate the pathology of metabolic disorders. The role of inflammatory cytokine IL-6 in
obesity and insulin resistance remains controversial. Although it has been proposed that IL-6
plays a detrimental role in impairing glucose homeostasis and insulin sensitivity 45, a recent
study points to the beneficial effect of IL-6 by promoting insulin secretion and the
maintenance of glucose homeostasis in diet-induced or genetic animal models 46.
Two recent studies showed that cholesterol crystals activate the NLRP3 inflammasome and
IL-1β release in mouse and human macrophages, thus highlighting a posible role of NLRP3
inflammasome in atherosclerosis 47, 48. The accumulation of a small amount of cholesterol
crystals was observed in early diet-induced atherosclerotic lesions, which was associated
with the recruitment of inflammatory macrophages 47. Cholesterol crystals generated in vitro
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activate caspase-1 and both IL-1β and IL-18 cleavage in LPS-primed human peripheral
blood mononuclear cells and mouse macrophages, which is dependent on NLRP3 and
ASC 47, 48. Moreover, cholesterol crystal-induced NLRP3 inflammasome activation was
sensitive to cytochalasin D and bafilomycin treatment, suggesting the requirement of
phagocytosis and lysosome acidification for inflammasome activation, which is consistent
with NLRP3 inflammasome activation induced by other crystals such as MSU, silica,
asbestos and alum 49–52. In line with the in vitro data, hypercholesterolemic LDL receptor
deficient (Ldlr−/−) mice reconstituted with bone marrow from Nlrp3−/−, Pycard−/− or
Il1b−/− mice developed significantly less atherosclerotic plaques than those reconstituted
with WT bone marrow 30. These findings suggest critical roles of hematopoietic cell-derived
NLRP3, ASC and IL-1β in the development of atherosclerotic lesions. However, the crucial
role of the NLRP3 inflammasome in atheroscleosis was challenged by another study using a
double-mutant crossing Apoe−/− mice with Nlrp3−/−, Pycard−/− or Casp1−/− mice 53. This
study failed to find any differences in atherosclerosis progression, infiltration of plaques by
macrophages, or plaque stability in the presence or absence of the NLPR3 inflammasome.
The obvious difference between these two studies is the investigation of hematopoietic-
derived versus whole body-derived NLRP3 inflammasome in the development of
atherosclerosis. It is quite clear that the NLRP3 inflammasome may also function in the
stromal compartment to regulate disease progression in addition to the hematopoietic
compartment, especially in the colitis and colitis-associated cancer 54, 55. Therefore, further
investigations are required to clarify these differences.
The inflammasome in gout
Gout is historically known as a disease of Kings since it is believed to result from a rich diet
and in particular those high in purines. It is associated with elevated levels of uric acid
(hyperuricemia) in the blood which forms crystals and are then deposited in joints. Uric acid
can be released from dying cells which activates cells as a danger signal 56. It is generally
accepted that IL-1β plays an important role in the promotion of inflammatory responses in
joints, supported by several recent clinical trials where the treatment of gout with anakinra
or other drugs that inhibit IL-1β showed amelioration of symptoms 57–60.
The mechanisms by which urate crystals cause inflammatory arthritis and IL-1β is generated
remain largely unknown until the NLRP3 inflammasome was identified as the link between
urate crystals and gout 49. MSU and calcium pyrophosphate dihydrate (CPPD) induce the
cleavage of caspase-1 and IL-1β or IL-18 in LPS-primed macrophages that is dependent on
NLRP3 and ASC. In vivo, NLRP3 inflammasome-mediated IL-1β generation promotes
neutrophil recruitment and peritoneal inflammation induced by MSU. A question that
remains is the mechanism whereby MSU or other crystal structure activates the NLRP3
inflammasome. Unlike other germline-encoded pathogen recognition receptors, there is no
evidence to suggest a direct recognition of danger signals by NLRP3. Therefore it is
reasonable to argue that the NLRP3 inflammasome detects some forms of alterations in
cellular homeostasis induced by danger signals. One such proposed signal has been
increased ROS generation 8. One study suggests that the thioredoxin-interacting protein
(TXNIP), a protein upregulated by glucose and linked to insulin resistance, interacts with
NLRP3, leading to IL-1β release 10. Inflammasome activators induce the transfer of TXNIP
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from thioredoxin to NLRP3 in a process involving ROS. However, this finding has been
challenged by a recent study, particularly in macrophages 17. A very recent study identified
caspase-1 interacting proteins including cellular inhibitors of apoptosis protein 1 (cIAP1),
cIAP2 and an adaptor protein TRAF2, which are required for spontaneous and agonist-
induced caspase-1 cleavage 61. The cIAP E3 ligase activity mediates lysine 63-linked
polyubiquitination of caspase-1, although its functional relevance to caspase-1 maturation
remains to be explored. Other potential mechanisms of the inflammasome activation involve
the participation of additional effector molecules such as other NLR molecules or pathogen
recognition receptors (PRR) such as Toll-like receptor (TLR) and RIG-I-like receptor
(RLR). For example, NAIP (NLR family, apoptosis inhibitory protein) proteins mediate the
NLRC4 inflammasome activation through a direct ligand-binding mechanism 62.
Prokaryotic messenger RNA promotes the NLRP3 inflammasome activation through a TRIF
(TIR domain-containing adaptor protein inducing IFN-β)-dependent manner, which is an
adaptor protein downstream of TLR3 and TLR4 63. RNA virus-induced activation of RIG-I
signaling leads to inflammasome activation 64. However, earlier studies have noted the
transcriptional induction of NLRP3 by microbes 65, 66, while a recent study suggests that
ROS induces the expression of NLRP3 67. Hence the transcriptional effects on components
of the inflammasome in addition to post-translational effects have to be taken into
consideration.
Although it has been well documented that crystal structure such as MSU, silica, asbestos
and alum induce NLRP3 inflammasome-dependent caspase-1 and IL-1β or IL-18 cleavage,
particularly in vitro 49–52, recent studies have observed NLRP3 inflammasome-independent
effects of uric acid, silica and alum in the development of TH2 immune response and TH2-
associated IgE antibody response 68, 69. One study shows that uric acid is released in the
airways of asthmatic patients and allergen-challenged mice and promotes TH2 immune
response by activating dendritic cells via spleen tyrosine kinase (Syk) and PI3-kinase δ
signaling pathways 54. Another study reports that silica and alum promote prostaglandin E2
(PGE2) production in macrophages through the Syk-p38 pathway, which enhances TH2
response-associated IgE production 68, 69. Both of these studies found that NLRP3 had no
effect. Therefore, crystals including alum adjuvant are found to induce both NLRP3
inflammasome-dependent and -independent immune effects. Further investigation is
warranted to clarify the role of the inflamamsome in these responses in physiologic settings.
Metabolic changes in inflammatory signaling
Another interesting aspect regarding IL-1β concerns the role of glucose metabolism in IL-1β
gene transcription. As mentioned above, in pancreatic β cells, glucose was shown to boost
production of IL-1β, although no mechanism was provided 19. This is less evident in
macrophages, where although glucose is required, high levels (mM) do not boost the
response. However, treating macrophages with 2-deoxyglucose (2-DG) was found to inhibit
transcription of IL-1β induced by LPS, but had no effect on TNF gene transcription 17. 2-DG
inhibits glycolysis by acting as a competitive substrate for hexokinase, thereby limiting
glucose metabolism. Why would this affect IL-1β gene transcription?
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LPS has been shown to have a profound effect on the metabolic profile of target cells. In
dendritic cells LPS promotes aerobic glycolysis – a process termed the Warburg effect 70, 71.
Warburg had originally defined this process in tumor cells, whereby respiration and the
Kreb’s cycle (also known as the tricarboxylic acid (TCA) cycle) in mitochondria is limited,
and glycolysis is enhanced. Several reasons for this metabolic shift have been proposed,
notably increased ATP production to meet the energy demands of the tumor cells.
Glycolysis, although less able to generate ATP, can be greatly enhanced via induction of the
enzymes involved 72. A second reason is for biosynthesis since intermediates for
biosynthesis of amino acids, lipids and nucleotides are made from glycolysis 73. This could
in fact be a mechanism for increased production of uric acid in inflammation, in the case of
the pentose phosphate pathway. The mechanism of the Warburg effect in tumors has
recently been shown to involve induction of the embryonic pyruvate kinase M2 (PKM2)
isoform 74, which strongly promotes hypoxia-inducible factor (HIF)-1α induction 75. PKM2
occurs in a complex with HIF-1α and prolyl hydroxylase 3 (PHD3) on the HIF-1α promoter.
HIF-1α induces glycolytic enzymes, promoting the glycolytic flux 76. This same process
could be happening in response to LPS, since LPS stabilizes HIF-1α via an as yet ill-defined
mechanism, and HIF-1a-deficient (Hif1a−/−) macrophages are defective in their responses to
LPS 77. LPS has also been shown to induce the ubiquitous isoform of 6-phosphofructo-2-
kinase/fructose-2,6-bisphosphatase (uPFK2), which strongly promotes glycolysis 78.
Attenuation of uPFK2 thus limits macrophage responses to LPS 78. Another mechanism
might involve decreased expression of PHD2 and PHD3 which would stabilize HIF-1α 79.
2-DG will block the flux through glycolysis and has been shown to inhibit various LPS
responses, including induction of IL-1β transcription and other gene products such as CD40,
CD80 and CD86 70.
The signal coming from glycolysis for these responses is not known but could also involve a
signal from mitochondria, since LPS also affects mitochondrial metabolism. LPS can limit
mitochondrial metabolism and oxidative phosphorylation although again the mechanism is
unknown 80. There is a decrease in the expression of genes encoding multiple proteins
involved in mitochondrial function 27. This could lead to a build-up of intermediates such as
succinate, which is a known inhibitor of PHD2, the enzyme that hydroxylates HIF-1α
leading to its degradation 81. Succinate would therefore increase HIF-1α levels. Also, a
build-up of ROS in response to LPS can play a role in the induction of HIF-1α 82. 2-DG has
been shown to lower ROS and succinate production providing a possible explanation for
how it blocks induction of IL-1β by LPS 83. It has also been shown that the ATP produced
from glycolysis is required for maintenance of the mitochondrial membrane potential in the
face of mitochondrial shut-down 84.
In essence therefore, LPS signaling via TLR4 involves an alteration in intracellular
metabolism which is determining for LPS responses. The shift to aerobic glycolysis is
required for induction of IL-1β mRNA. The inflammasome is activated by hyperlipidemia
leading to increased IL-1β production. The IL-1β then causes insulin resistance and
decreased fatty acid oxidation in the mitochondria. These events promote obesity, producing
a vicious cycle which is further enhanced by the increased IAPP production in the pancreas,
IAPP being synthesized in concert with insulin, and having the biochemical trait of forming
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amyloid. IAPP promotes further IL-1β production, which ultimately is toxic to β cells in the
pancreas. It should be noted however that a causal link between IAPP and the pathogenesis
of T2D, although intriguing as an hypothesis, has yet to be proven. A similar scenario could
be occurring in atherosclerosis, where cholesterol crystals exacerbate the inflammatory
process via NLRP3, with this process promoting plaque formation. TLR4 could be a key
driver in these events since it responds to fatty acids and also minimally oxidized LDL,
providing for pro-IL-1β and priming the inflammasome. The shift to the Warburg effect
could therefore be determining for inflammation (events summarized in Fig 2).
Another example of the Warburg effect being important for inflammation was highlighted
by a report on TH17 cells. HIF-1α enhances TH17 development via activation of RORγt and
p300 recruitment to the IL-17 promoter 85. HIF-1α also attenuates regulatory T (Treg) cell
development by binding to their lineage-specifying transcription factor Foxp3 and targeting
it for proteosomal degradation. Hif1a−/− mice could not generate TH17 cells and were
resistant to EAE 85. Similar results were obtained in another study and even more strikingly,
it was shown that HIF-1α dependent glycolysis was acting as a metabolic checkpoint for the
differentiation of TH17 cells 86. Importantly, 2-DG could convert a TH17 cell into a Treg
cell 86. Since TH17 are the more pro-inflammatory cell type, this further emphasizes how the
Warburg effect is determining for inflammation, being important for both inflammatory
cytokine production from macrophages and dendritic cells and the generation of TH17 cells.
Why would IL-1β cause insulin resistance? There are two possible options. Insulin
resistance mainly occurs in liver and smooth muscle cells, and is though to involve induction
of SOCS2 and SOCS3 87, as well as activation of Jun N-terminal kinase and IκB kinase 88,
to limit insulin signaling. This could spare glucose for macrophages, which require the
glucose for energy demands and biosynthesis, both of these involve the switch to aerobic
glycolysis, probably via HIF-1α (Fig 2). A second possibility is to limit glucose uptake in a
negative feedback loop, since this could impair further IL-1β transcription and would also
limit production of ROS from mitochondria. In T2D however, the on-going induction of
IL-1β in response to the various stimuli including IAPP suggests any negative feedback
effect is over-whelmed, and IL-1β then becomes pathogenic.
Conclusions
A wealth of evidence therefore points to an intimate relationship between IL-1β, the NLRP3
inflammasome and lipid and carbohydrate metabolism. This occurs at the level of enhanced
NLRP3 inflammasome activation and IL-1β processing to the mature cytokine in response to
saturated fatty acids, and also glucose metabolism via glycolysis being required for
induction of mRNA encoding IL-1β. Glycolysis and HIF-1α have also been shown to be key
for TH17 cell differentiation. The pathogenic role played by IL-1β in plaque formation in
atherosclerosis, and in insulin resistance and β cell loss in T2D attests to the importance of
these processes in these metabolic diseases. The exacerbation of NLRP3 inflammasome
activation by cholesterol crystals in atherosclerosis, and IAPP in T2D provides positive
feedback loops to promote disease pathogenesis. Uric acid crystals, which are another
consequence of metabolic disorder, are also NLRP3 inflammasome activators which lead to
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IL-1β production in gout. The hope is that the recent insights into the molecular basis of
these diseases will help in the design of new therapies.
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A model for the pathogenesis of T2D: adipose tissue, the pancreas, NLRP3 and T2D. In
adipose tissue, elevated levels of saturated free fatty acids decrease the activity of AMPK, a
central regulator of energy biosynthesis and lipid metabolism, leading to defective
autophagy of mitochondria (Mitophagy). The accumulation of dysfunctional mitochondria
then enhances mitochondrial ROS generation and the release of mitochondrial DNA into
cytosol, both of which promotes NLRP3 inflammasome activation and IL-1β release. The
active IL-1β induces the activation of JNK and IKK through IL-1 receptor, which impair the
insulin-insulin receptor (IR), insulin receptor substrate-1 (IRS-1), and PI3K-Akt signaling
pathway. In the pancreas, the accumulation of IAPP activates the NLRP3 inflammasome
and promotes IL-1β release from macrophages, which causes β-cell dysfunction and death.
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Metabolic fluxes, NLRP3 and IL-1β. Hyperlipidemia in the form of saturated fatty acids
such as palmitate, has been shown to activate the NLRP3 inflammasome leading to
caspase-1 activation and the processing of pro- IL-1β. Impaired mitochondrial metabolism,
including decreased β-oxidation of fatty acids, could promote this process, as will
production of reactive oxygen species. Activation of TLR4 by LPS or minimally modified
oxidized LDL promotes glycolysis via induction of enzymes such as uPFK2 leading to
enhanced ATP production and nucleotide biosynthesis via the pentose phosphate pathway.
Purines including uric acid, could be over-produced via this process leading to NLRP3
inflammasome activation. IL-1β will give rise to insulin resistance, causing enhanced IAPP
production, which in turn will further activate NLRP3. Insulin resistance in liver and muscle
could spare glucose for macrophages. See text for details.
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